What is CMS physician shared patient patterns data?

CMS Physician Shared Patient Patterns data is a publicly available dataset from the Centers for Medicare & Medicaid Services that captures when two or more providers share a minimum number of Medicare patients within a defined window (30, 60, 90, or 180 days). Life sciences commercial teams use it to infer referral relationships and map patient flow across physician and care settings.

How do medtech companies use referral network data for HCP targeting?

Medtech commercial teams use referral network data to identify which physicians are sending patients to their high-priority proceduralists, uncover feeder accounts sustaining procedure volume at key surgery centers, and expand target lists to include high-volume referring physicians who influence downstream procedure decisions.

How is referral data different from procedure volume data?

Procedure volume data from CPT/HCPCS claims tells you which physicians are performing relevant procedures and at what volume. Referral network data tells you how patients flow to those physicians — which PCPs or specialists are referring patients, and in what volume. Together, they give commercial teams a complete picture of the clinical pathway rather than just the endpoint.

Can pharma companies benefit from HCP referral intelligence?

Yes. For specialty therapies, referral intelligence helps pharma commercial teams identify primary care or referring physicians who most influence specialist prescribing — through the volume and case mix of patients they refer. This surfaces high-value HCPs who may not appear on standard prescribing reports but who shape the patient population a specialist sees.

What should I look for in a commercial intelligence platform that includes referral data?

Key criteria include: whether the platform uses CMS shared-patient data, all-payor data, or both; whether referral networks can be filtered by geography, specialty, and volume; how frequently the data is refreshed; and whether referral data can be layered with CPT/HCPCS procedure volume, ICD-10 codes, and HCP affiliation data in a single view.

Insights

Referral Network Intelligence: How MedTech and Pharma Teams Use CMS Shared-Patient Data to Map HCP Influence

Isabel Wellbery • Sun May 31 2026

Omnichannel Marketing Industry Trends Healthcare Data & Analytics MedTech Sales

Referral Network Intelligence: How MedTech and Pharma Teams Use CMS Shared-Patient Data to Map HCP Influence

Summarize with AI

On this page

Most commercial targeting strategies start and end with specialty and geography. But the physicians driving the most patient volume at your highest-priority accounts often aren’t the ones your reps are calling on. They’re the referral hubs — the PCPs, proceduralists, and hospital-based specialists whose referral decisions shape clinical pathways upstream of the prescribing or procedure event.

CMS publishes its Physician Shared Patient Patterns dataset as part of its broader data transparency initiative, yet most life sciences commercial teams leave this intelligence untapped. For medtech and pharma commercial leaders who have already optimized their call plans and territory design, referral network intelligence is the next layer of precision — one that can meaningfully expand your addressable market and surface accounts your current model is missing.

What Is CMS Shared-Patient Referral Data?

The Centers for Medicare & Medicaid Services publishes the Physician Shared Patient Patterns dataset, which captures instances where two or more providers share a minimum number of patients within a defined time window — typically 30, 60, 90, or 180 days. It doesn’t capture formal referral records; instead, it surfaces inferred patient-sharing relationships derived from millions of Medicare encounters.

For life sciences commercial teams, this creates a de facto referral map. Instead of targeting physicians in isolation — by specialty, NPI, or procedure volume alone — you can now see which physicians are connected to your key targets, where patients flow before and after a procedure or prescription event, and which PCPs or specialists are feeding volume into your highest-priority accounts.

The dataset is large and complex, requiring significant data engineering to operationalize at scale. The best commercial intelligence platforms surface referral relationships alongside CPT/HCPCS procedure volume, HCP affiliations, and ICD-10 billing data in a single view — making the intelligence actionable without needing a dedicated data science team.

Why Referral Patterns Change Everything for MedTech Account Targeting

For medtech companies selling into surgical or procedural specialties, the decision to treat often begins not with the surgeon, but with the referring physician who identifies the candidate patient. A spine surgery case involves a proceduralist — but the referral pathway typically runs through a primary care physician, neurologist, or pain management specialist. Key trends reshaping MedTech commercialization in 2026 consistently identify referral pathway intelligence as an underutilized lever in commercial strategy.

Procedure-level CPT data tells you which physicians are performing high volumes of relevant codes — but referral network data tells you who is sending patients to those physicians, and in what volume. If your commercial team is targeting proceduralists while ignoring the referral network feeding them, you’re leaving a significant share of the addressable opportunity unaddressed.

This matters at the account level too. A surgery center or hospital system that appears to be a high-priority account based on procedure volume may have that volume sustained by a handful of high-referral PCPs. If those PCPs shift their referral behavior — because a competitor engaged them, or because a new practice joined their network — the account’s volume follows. Monitoring referral concentration risk is as important as monitoring procedure volume.

The Pharma Application: Finding the Hidden HCPs Who Drive Prescribing

Specialty therapies are often prescribed by a small population of high-volume specialists, but those specialists’ decisions are frequently shaped by referring physicians who champion or gatekeep access. A rheumatologist’s prescribing of a biologic therapy, for example, may be influenced by the volume and acuity of cases referred by primary care physicians.

Commercial teams are using referral analytics to identify high-value PCPs who frequently refer to their top specialist targets, map “feeder” accounts to key hospital systems or specialty practices, and surface physicians who don’t appear on standard prescribing reports but who influence specialist behavior through referral volume and patient case mix.

This is especially valuable for identifying “no-see” HCPs who don’t meet with sales reps but who carry significant upstream influence over the prescribing or procedure decisions your commercial team cares about. For a deeper look at engaging this physician cohort, see Data-Driven Strategies for Engaging No-See HCPs.

Using Referral Data to Map KOL and Thought-Leader Networks

Medical affairs teams apply referral intelligence differently: not just to find high-volume referrers, but to map clinical influence networks. A physician who appears as a highly central node in a referral graph — connected to many specialists, multiple institutions, across geographic areas — often carries significant clinical influence even if they don’t publish frequently or hold formal leadership roles.

This is particularly useful for identifying emerging or regional KOLs who don’t surface in publication databases but who shape local practice patterns through referral relationships. When combined with procedure volume and institutional affiliation data, referral centrality gives medical affairs a far more complete picture of who to engage — and in what sequence — than publication counts or conference activity alone.

Research on U.S. physician referral networks shows that network centrality is a stronger predictor of clinical influence than volume alone, particularly in specialty-heavy markets. Commercial intelligence platforms that surface both referral centrality and CPT-level procedure volume in a unified HCP profile make this segmentation straightforward to act on.

Operationalizing Referral Intelligence: A Practical Playbook

Here is how leading life sciences commercial teams translate referral data into targeting decisions:

Start with your target HCPs. Using CPT/HCPCS procedure data, identify physicians performing the highest volumes of relevant codes in each territory.
Map their referral networks. Pull shared-patient data to surface which physicians are sending them the most patients — and which physicians they, in turn, are referring to.
Prioritize accounts based on referral centrality. Physicians at the center of large, dense referral networks represent accounts where influencing referral behavior compounds returns: one engaged referrer can shift volume across multiple downstream procedure events.
Expand your target list to include high-value referrers. These physicians may not appear on your initial call plan — they may not prescribe your therapy or perform relevant procedures themselves — but engaging them can meaningfully shift territory-level volume.
Monitor referral pattern changes over time. Physician networks shift as practices merge, specialists retire, and new graduates join local networks. Referral data that refreshes regularly gives you early warning when account-level volume dynamics are about to change.

The teams seeing the sharpest improvements in coverage model efficiency are those treating referral patterns as a dynamic, ongoing intelligence feed rather than a static enrichment layer. For a broader framework on demonstrating data-driven ROI from targeting, see Proving ROI in HCP Targeting.

What to Look for in a Commercial Intelligence Platform

Not all platforms surface referral data with equal depth or usability. Five forces reshaping pharma commercialization in 2026 all point toward integrated, real-time data infrastructure as the defining competitive differentiator. When evaluating solutions, the right questions are:

Does the platform use CMS shared-patient data, proprietary all-payor data, or both?
Can you filter referral networks by geography, specialty, and volume thresholds?
Is referral data refreshed on a cadence that aligns with your planning cycles?
Can you layer referral relationships on top of CPT/ICD-10 procedure volume and HCP affiliation data in a single view?

The best platforms let commercial teams start from a target specialty or procedure code, build out a referral network map, and export a prioritized HCP list without needing a data science team. For a detailed look at how today’s leading solutions compare on these dimensions, see Choosing the Right HCP Targeting and Commercial Intelligence Tool in 2026.

Conclusion

Referral network intelligence isn’t a replacement for your existing HCP targeting strategy — it’s the upstream layer your strategy has likely been missing. Most commercial targeting models account for what physicians do; referral data tells you how patients get to them and, critically, who influences that flow.

The commercial teams gaining the sharpest targeting advantage in 2026 are the ones layering referral data on top of procedure volume and HCP profiles to build a fuller picture of how clinical decisions actually get made. If your current model doesn’t account for referral patterns, you’re almost certainly leaving high-value HCPs and accounts off your call plan.

CMS shared-patient data gives you the map. The question is whether you’re using it.

Alpha Sophia surfaces CMS referral intelligence alongside procedure volume, CPT/HCPCS codes, and full HCP profiles in a single platform. Book a demo to see your territory’s referral network in action.